Adherence and patients’ experiences with capecitabine.

Adherence and patients' experiences with the use of capecitabine in cancer treatment: The exploration of factors affecting the use in daily practice.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21382

Enrollment

Registered

2010-05-11

Start date

2010-02-09

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, gastric cancer and breast cancer.

Interventions

The use of capecitabine in daily practice will be monitored for 5 cycles. Every cycle takes three weeks.

Eligibility

Inclusion criteria

Inclusion criteria: Cancer patients starting with capecitabine.

Exclusion criteria

Exclusion criteria: Younger than 18 years of age or insufficient knowledge of the Dutch language.

Design outcomes

Primary

Measure	Time frame
Adherence rate: A patient is adherent with the intake of 85% or more of the prescribed medication.	—

Secondary

Measure	Time frame
1. Number and grade of side-effects; 2. Attitude towards disease; 3. Beliefs and attitude towards medicines.	—

Contacts

Public ContactL. Timmers

+31 (0)20 4442777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)